Event

Accelerating & de-risking clinical development at EACPT

Prague • 24 Jun 2017 - 27 Jun 2017

The earlier information concerning pharmacokinetics, efficacy and safety of a candidate drug in humans is available, the better. Microtracers can be used to increase the information density in your early clinical trials. The information on metabolites in First-In-Man studies will de-risk the clinical development trajectory because of the 100% certainty of not finding any human unique metabolites at a later stage. TNO is the only organization in Europe with a biomedical Accelerator Mass Spectrometer (AMS) that enables this research.

At the EACPT annual meeting, from 24-27 June in Prague, TNO will present its capabilities in the field of human microtracer AMS studies and in vitro microbiome based metabolism studies.

The focus and experience of TNO in the field of microtracer research extends to:

  • Absolute bioavailability in early clinical development.
  • Metabolite profiling and identification in First-In-Man studies.
  • Early PK of biologicals (peptides, proteins, ADCs etc) and small molecules using microdosing.
  • Pediatric PK studies optimizing, dosing strategies, addressing MIST and increasing recruitment rates.
  • Targeted cancer therapy via cocktail-dosing of 14C labeled antibodies to cancer patients. Therapy with selected candidate based on investigating target specificity after surgical operation followed by AMS analysis on biopsies.

In addition, we will show the strengths of using our simultaneous data acquisition using high resolution MS (for metabolite identification) and AMS (for metabolite quantification) approach.

Further we will present how our in vitro platform I-screen, using microbiota of different (human) origin can be used to identify microbiome induced metabolism.

We look forward to meeting you at our booth, number 7.

We use anonymous cookies to enhance the use of our site.